3-(4-甲基苯氧基)苯甲酸 | 62507-86-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(4-甲基苯氧基)苯甲酸
• 英文名称: 3-(p-tolyloxy)benzoic acid
• 英文别名: 3-(4-Methylphenoxy)benzoic acid
• CAS: 62507-86-2
• 化学式: C₁₄H₁₂O₃
• mdl: MFCD03840106
• 分子量: 228.247
• InChiKey: JDFNHFHOMMSCEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  3-(4-甲基苯氧基)苯甲酸 在 硫酸 、 一水合肼 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 3-(4-methylphenoxy)-N'-(2-oxoindol-3-yl)benzohydrazide
  参考文献：
  名称：

  Nagarapu, Lingaiah; Ravirala, Narender; Akkewar, Dattatray M., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1998, vol. 37, # 12, p. 1254 - 1257

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(4-甲基苯氧基)苯甲醛 在 rat hepatic microsomal aldehyde dehydrogenase 、 β-烟酰胺腺嘌呤二核苷酸 作用下， 以 phosphate buffer 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-(4-甲基苯氧基)苯甲酸
  参考文献：
  名称：

  Rat Hepatic Microsomal Aldehyde Dehydrogenase. Identification of 3- and 4-Substituted Aromatic Aldehydes as Substrates of the Enzyme

  摘要：

  The rat hepatic microsomal aldehyde dehydrogenase (mALDH) metabolizes aliphatic and aromatic aldehydes to the corresponding acids with NAD as the optimal cofactor. However, dehydrogenation of the aliphatic compounds is substantially more efficient. In the present study, a series of aromatic aldehydes was evaluated as substrates of the purified mALDH so that the physicochemical factors that contribute to substrate affinity could be evaluated. Substitution of the aromatic system in the 3- and 4-positions produced relatively good substrates, but 2-substituted congeners did not undergo dehydrogenation. However, aldehydes with hydrophilic substituents in the 3- or 4-positions and those with extremely bulky substituents at both positions (e.g., 3,4-dibenzyloxy) were also poor substrates for the enzyme and dehydrogenation was undetectable. A quantitative structure-activity relationship was determined that related the logarithm of the Michaelis constants for 27 substituted aromatic aldehydes with the zero-order connectivity function of the molecule ((0) chi), the shapes of the 3- and 4-substituents (kappa), and the electronic nature of the 4-substituent (sigma). In this equation, 81% of the data variance was explained. From a consideration of the dimensions of 3-phenoxybenzaldehyde, which was a relatively good substrate, the mALDH possesses a narrow cleft within the active site that is at least 7.5 Angstrom wide and extends at least 12 Angstrom from the the catalytic residue (probably cysteine). Previously established relationships between connectivity functions and molecular polarizability suggest that dipolar interactions within the active site, as well as dispersion forces, may play a role in substrate specificity. Although optimal shapes for carbocyclic substituents were not provided by the analysis, the unfavorable effect on dehydrogenation from hydrophilic and large substituents suggests that the active site of the mALDH is relatively rigid and that the orientation of the substrate in relation to the catalytic cysteine and the cofactor binding site is critical.

  DOI：

  10.1021/tx950106l

文献信息

• INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
  申请人：Dumas Jacques

  公开号：US20120046290A1

  公开（公告）日：2012-02-23

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.

  本发明涉及一组芳香脲在治疗细胞因子介导的疾病（除癌症外）和蛋白水解酶介导的疾病（除癌症外）中的用途，以及用于此类治疗的药物组合物。
• INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS
  申请人：Dumas Jacques

  公开号：US20070244120A1

  公开（公告）日：2007-10-18

  Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

  治疗由raf激酶介导的肿瘤的方法，包括使用取代脲化合物，以及这些化合物本身。
• Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0425134A1

  公开（公告）日：1991-05-02

  A heterocyclic compound of the formula (I): and a pharmacologically acceptable salt thereof which have platelet activating factor (PAF) antagonizing activity are disclosed.

  公开了一种具有血小板活化因子（PAF）拮抗活性的化学式（I）的杂环化合物及其药理学上可接受的盐。
• Rhodium(III)-catalyzed Intramolecular Ar–H/Ar–H Coupling Directed by Carboxylic Group to Produce Dibenzofuran Carboxylic Acids
  作者：Takeshi Okada、Yuto Unoh、Tetsuya Satoh、Masahiro Miura

  DOI：10.1246/cl.150739

  日期：2015.11.5

  The rhodium-catalyzed intramolecular Ar–H/Ar–H coupling of 3-phenoxybenzoic acids proceeds smoothly, accompanied by double C–H bond cleavage at the 2- and 2′-positions, to produce dibenzofuran-1-carboxylic acid derivatives. Related tetra- and pentacyclic molecules can also be readily constructed by the present procedure. A reaction mechanism involving 1,4-rhodium(III) migration is proposed.

  在铑催化下，3-苯氧基苯甲酸的分子内 Ar-H/Ar-H 偶联顺利进行，同时在 2- 和 2′-位发生双 C-H 键裂解，生成二苯并呋喃-1-羧酸衍生物。相关的四环和五环分子也很容易通过本程序生成。提出了一种涉及 1,4-铑(III)迁移的反应机理。
• Pyrrolidine derivative or salt thereof
  申请人：Hachiya Shunichiro

  公开号：US20090062366A1

  公开（公告）日：2009-03-05

  [Problem] To provide a compound which may be used in treating diseases in which a calcium sensing receptor (CaSR) is concerned, particularly hyperparathyroidism. [Means for Resolution] It was found that novel pyrrolidine derivatives which are characterized by the possession of aminomethyl group substituted with arylalkyl group or the like, or salts thereof, have excellent CaSR agonistic regulatory activity and also have excellent selectivity with CYP2D6 inhibitory activity having a possibility of causing drug interaction. Based on the above, these novel pyrrolidine derivatives are useful as therapeutic agents for treating diseases in which CaSR is concerned (hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like).

  [问题] 提供一种可用于治疗钙敏感受体（CaSR）相关疾病，特别是甲状旁腺功能亢进症的化合物。 [解决方法] 发现了一种新型吡咯烷衍生物，其特征在于具有氨甲基基团，该基团被芳基烷基或类似物取代，或其盐，具有出色的CaSR激动调节活性，并且具有出色的选择性与CYP2D6抑制活性，可能导致药物相互作用。基于以上发现，这些新型吡咯烷衍生物可用作治疗CaSR相关疾病（甲状旁腺功能亢进症，肾性骨营养不良，高钙血症等）的治疗剂。